Sources

[←1]

^{Swift, W., et al. Survey of Australians using cannabis for medical purposes. Harm Reduction Journal (2005) 4: 2-18}

[←2]

^{Ware, M., et al. The medicinal use of cannabis in the UK: results of a nationwide survey. International Journal of Clinical Practice (2005) 59: 291-295}

[←3]

^{Nunberg, H., et al. An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California. Journal of Dug Policy Analysis (2011) Volume 4}

[←4]

^{Malfait, A., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Science of the USA. (2000) 97: 9561-9566}

[←5]

^{Mechoulam, R., et al. Cannabidiol recent advances. Chemistry & Biodiversity (2007) 4: 1678–1692}

[←6]

^{Carrier, E. Inhibition of an equilibrative nucleosidetransporter by cannabidiol: a mechanism of cannabinoidimmunosuppression. Proceedings of the National Academy of Science of the USA. (2006) 103: 7895–7900}

[←7]

^{Evans FJ. Cannabinoids: The separation of central from peripheral effects on a structural basis. Planta Med. 1991;57:S60–7.}

[←8]

^{Blake, D., et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (2006) 45: 50-52}

[←9]

^{Malfait, A., et al.}

[←10]

^{Sumariwalla, P., et al. A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with anti-inflammatory properties in murine collagen-induced arthritis. Arthritis & Rheumatism (2004) 50: 985-998}

[←11]

^{Croxford, J., Cannabinoids and the immune system: potential for the treatment of inflammatory diseases. Journal of Neuroimmunology (2005) 166: 3-18}